This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

2022 Information Coming Soon!

Paul Hughes, Ph.D.
Scientific Director at Amgen


Since joining Amgen in 2003 my research has been focused on the discovery of novel small and large molecule oncology therapeutics. My group contributed to the discovery of AMG 757, a first-in-class DLL3-targeted bispecific T-cell engager molecule BITE molecule targeting DLL3. I’m currently actively engaged in cross-functional teams to develop novel targeted therapies focused on drugging proteins that are genetically altered in cancer.

Agenda Sessions

  • Advances in T-Cell Engaging Therapies

  • Preclinical Activity of the DLL3-targeting BiTE Molecule AMG 757 in Small Cell Lung Cancer

    On Demand

Speakers at this event